Patents by Inventor Simon Fraser Campbell

Simon Fraser Campbell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocyclic Compounds and Uses Thereof
    Publication number: 20230321050
    Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
    Type: Application
    Filed: November 9, 2022
    Publication date: October 12, 2023
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson, Simon Fraser Campbell
  • Heterocyclic compounds and uses thereof
    Patent number: 11547697
    Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: January 10, 2023
    Assignee: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson, Simon Fraser Campbell
  • Heterocyclic Compounds and Uses Thereof
    Publication number: 20190350906
    Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
    Type: Application
    Filed: December 6, 2018
    Publication date: November 21, 2019
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson, Simon Fraser Campbell
  • Heterocyclic Compounds and Uses Thereof
    Publication number: 20180042902
    Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
    Type: Application
    Filed: April 25, 2017
    Publication date: February 15, 2018
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson, Simon Fraser Campbell
  • Substituted benzimidazoles as PI3 kinase inhibitors
    Patent number: 9359352
    Abstract: The present invention provides substituted benzimidazole compounds of Formula I: wherein the variables R1, R2, W1, W2, W3, W4, W5, W6, Wa, Wb, Wc and Wd are defined herein. The compounds are useful as phosphoinositide 3-kinase (PI3 kinase) inhibitors.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: June 7, 2016
    Assignee: Intellikine LLC
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson, Simon Fraser Campbell
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20150320727
    Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
    Type: Application
    Filed: June 2, 2015
    Publication date: November 12, 2015
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson, Simon Fraser Campbell
  • Heterocyclic Compounds and Uses Thereof
    Publication number: 20150322064
    Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
    Type: Application
    Filed: July 16, 2015
    Publication date: November 12, 2015
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson, Simon Fraser Campbell
  • Heterocyclic compounds and uses thereof
    Patent number: 9127000
    Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
    Type: Grant
    Filed: February 23, 2012
    Date of Patent: September 8, 2015
    Assignee: Intellikine, LLC.
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson, Simon Fraser Campbell
  • Substituted benzoxazoles as PI3 kinase inhibitors
    Patent number: 9096590
    Abstract: The present invention provides substituted benzoxazole compounds of the Formula: wherein the variables R1, R2, W1, W2, W3, W4, W5, are W6 are defined herein. The compounds are useful as phosphoinositide 3-kinase (PI3 kinase) inhibitors.
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: August 4, 2015
    Assignee: Intellikine LLC
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson, Simon Fraser Campbell
  • Heterocyclic compounds and uses thereof
    Patent number: 9085560
    Abstract: A method of inhibiting phosphatidyl inositol-3 kinase (PI3 kinase), comprising: contacting the PI3 kinase with an effective amount of a compound or pharmaceutically acceptable salt of the formula below, wherein the variables R1, R2, W1, W2, W3, W4, W5, are W6 are defined herein.
    Type: Grant
    Filed: August 17, 2010
    Date of Patent: July 21, 2015
    Assignee: INTELLIKINE, INC.
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson, Simon Fraser Campbell
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20150158859
    Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
    Type: Application
    Filed: February 23, 2012
    Publication date: June 11, 2015
    Applicant: Intellikine LLC
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson, Simon Fraser Campbell
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20130261102
    Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
    Type: Application
    Filed: May 24, 2011
    Publication date: October 3, 2013
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson, Simon Fraser Campbell
  • HETEROCYCLIC COMPOUNDS AND USES THEREOF
    Publication number: 20130035324
    Abstract: Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the heterocyclic entities, and methods of using these chemical entities for treating diseases and conditions associated with PI3 kinase activity are described herein.
    Type: Application
    Filed: August 17, 2010
    Publication date: February 7, 2013
    Inventors: Pingda Ren, Yi Liu, Liansheng Li, Katrina Chan, Troy Edward Wilson, Simon Fraser Campbell
  • cGMP-PDE inhibitors for the treatment of erectile dysfunction
    Publication number: 20040087599
    Abstract: Pyrazolopyrimidine compounds which are selective inhibitors of cGMP PDE are useful in the treatment of erectile dysfunction (impotence) in male animals, including man.
    Type: Application
    Filed: October 27, 2003
    Publication date: May 6, 2004
    Applicant: Pfizer Inc
    Inventors: Simon Fraser Campbell, Alexander Roderick Mackenzie, Anthony Wood
  • 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction
    Patent number: 6656945
    Abstract: 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one compounds which are selective inhibitors of cGMP PDE are useful in the treatment of erectile dysfunction (impotence) in male animals, including man.
    Type: Grant
    Filed: June 13, 2001
    Date of Patent: December 2, 2003
    Assignee: Pfizer Inc
    Inventors: Simon Fraser Campbell, Alexander Roderick MacKenzie, Anthony Wood
  • Bicyclic heterocyclic compounds for the treatment of impotence
    Patent number: 6534511
    Abstract: The use of certain 6-arylpyrazolo[3,4-d]pyrimidin-4-ones, 2 arylquinazolin-4-ones, 2-arylpurin-6-ones and 2-arylpyrido[3,2-d]pyrimidin-4-ones, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the curative or prophylactic treatment of erectile dysfunction in a male animal, including man; a pharmaceutical composition for said treatment; and a method of said treatment of said animal with said pharmaceutical composition or with said either entity.
    Type: Grant
    Filed: April 3, 2000
    Date of Patent: March 18, 2003
    Assignee: Pfizer Inc.
    Inventor: Simon Fraser Campbell
  • 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one cGMP-PDE inhibitors for the treatment of erectile dysfunction
    Publication number: 20010044441
    Abstract: 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one compounds which are selective inhibitors of cGMP PDE are useful in the treatment of erectile dysfunction (impotence) in male animals, including man.
    Type: Application
    Filed: June 13, 2001
    Publication date: November 22, 2001
    Inventors: Simon Fraser Campbell, Alexander Roderick Mackenzie, Anthony Wood
  • 4-aminoquinazoline derivative cGMP-PDE inhibitors for the treatment of erectile dysfunction
    Patent number: 6300335
    Abstract: 4-aminoquinazoline derivatives which are selective inhibitors of cGMP PDE are useful in the treatment of erectile dysfunction (impotence) in male animals, including man.
    Type: Grant
    Filed: May 22, 1997
    Date of Patent: October 9, 2001
    Assignee: Pfizer Inc.
    Inventors: Simon Fraser Campbell, Alexander Roderick Mackenzie, Anthony Wood
  • Bicyclic heterocyclic compounds for the treatment of impotence
    Patent number: 6100270
    Abstract: A method of treating male erectile dysfunction comprising administering to a male human a pyrimidine compound of formula I.
    Type: Grant
    Filed: May 22, 1997
    Date of Patent: August 8, 2000
    Assignee: Pfizer Inc.
    Inventor: Simon Fraser Campbell